Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06047977 · ClinicalTrials.gov registry record · Phase 1
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
A Phase 1 study of Lymphocytes, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06047977 is a Phase 1 study of Lymphocytes that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06047977, a Phase 1 study of Lymphocytes, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors. Part Two of this study will determine the safety of TIL therapy with lymphodepleting chemotherapy and post-TIL Interleukin-2 in high-risk pediatric solid tumors
Conditions Studied
Interventions
- BIOLOGICAL Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
Study Locations (1)
Florida
- Johns Hopkins All Children's Hospital - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-02 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06047977
The ClinicalTrials.gov registry entry for NCT06047977 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphocytes appearing as the primary indexed condition, and to 1 intervention - of which Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2 is the first listed.
NCT06047977 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06047977 about?
NCT06047977 is a clinical study titled "Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors". Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors. Part Two of this study will determine the safety of TIL therapy with lymphodepleting chemotherapy and post-TIL Interleukin-2 in high-ris...
What is the current status of trial NCT06047977?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-06-02. Estimated completion is 2027-12-01.
What conditions does trial NCT06047977 study?
This clinical trial studies the following conditions: Lymphocytes.
What interventions are being tested in trial NCT06047977?
The interventions under investigation include: Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06047977?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06047977 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.